Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain
BETHESDA, MD–(Marketwired – Nov 6, 2014) – Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed an IP Licensing and Collaboration Agreement with Kalapa Holding (Spain) for the production and distribution of CANNABICS SR medical cannabis products in the Spanish market.
Kalapa Holding is a leading medical cannabis and hemp grower and distributor in Spain, with a diverse line of cannabinoid based products.
CANNABICS SR medical cannabis products will be available in strict compliance with Spanish laws and regulations to certified patients through the “Asociacion Centro Cannabico de Terapias Naturales,” a registered Spanish entity and affiliate of Kalapa Holding.
CANNABICS SR products will be manufactured and distributed in Spain locally, based on pure extracts produced from select, high quality and organic medical cannabis strains cultivated by the Asociacion Centro Cannabico de Terapias Naturales.
Dr. Zohar Koren, CEO of Cannabics Pharmaceuticals, stated, “We are very excited to launch the collaboration with Kalapa Holding in Spain and thus offer our line of advanced medical cannabis products to European patients for the first time. The substantial synergy that arises through the combination of the extensive operational capabilities and outreach of Kalapa Holding in the Spanish medical cannabis market, combined with our advanced cannabinoid administration technology, as embedded in the CANNABICS SR line of products, ensures that this is a long-term and sustainable partnership.”
Joan De Haro, CEO of Kalapa Holding, added, “We are delighted to initiate our collaboration with Cannabics Pharmaceuticals through the current IP licensing agreement and add the advanced line of CANNABICS SR products to our arsenal of high quality medical cannabis therapies. This achievement is a major milestone in our endeavor to become a leading company in the medical cannabis field in Spain, and it perfectly fits our strategy of connecting patients directly with doctors for exact personal tailoring of advanced and sophisticated medical cannabis therapies.”
About Cannabics Pharmaceuticals, Inc.
Cannabics Pharmaceuticals, Inc. is an emerging drug development company focused on the development and commercialization of advanced drugs, therapies, food supplements and administration routes based on the wide range of active ingredients found in diverse and unique strains of the Cannabis plant. Cannabics’ current flagship product is CANNABICS SR — an IP pending medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Cannabics’ proprietary SR technology provides 10-12 hours of steady state and beneficial therapeutic effects profile, and thus allows for a convenient oral, once-per-day or twice-per-day dosing regimen of medical cannabis for patients. Cannabics is now preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory pathways, while simultaneously preparing to launch a series of formal clinical studies in order to establish the unique medical benefits of its products for patients suffering from various indications.
For more information, visit www.cannabics.com
About Kalapa Holding, S.L.
Kalapa Holding S.L., headquartered in Barcelona, Spain, is dedicated to the development, production and distribution of nutritional supplements and para-pharmaceutical products based on cannabinoids and additional therapeutic plant extracts. Kalapa Holding controls a network of subsidiaries and affiliated organizations which cover the complete chain of production and distribution, including organic growing facilities, production laboratories, distribution channels and specialized patient care doctor’s offices. By controlling the entire process, high quality products as well as an instant feedback loop from patients for the reported therapeutic effects of the products is achieved. Kalapa Holding collaborates in this process with leading physicians in the main hospitals of Spain. Recently, Kalapa Holding has initiated an incubator for high quality projects in the field of medical cannabis, including R&D projects, production, distribution and digital data processing. In addition, Kalapa Holding consults Cannabis Associations in Spain on the formal development and rigorous control of their therapeutic and medical cannabis programs.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 15th, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
Corporate VP Marketing